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Abstract
Background: Severe weight loss through means of bariatric surgery has been associated with loss of muscle mass
due to lack of absorption of protein. The aim of this RCT is to investigate the effectiveness of protein
supplementation in reducing the risk of developing protein malnutrition and muscle wasting in post-bariatric
surgery patients in Qatar.
Methods and analysis: The study was based at the Department of bariatric and metabolic surgery, Doha
metropolitan and regional areas. It is envisaged that approximately 160 post-bariatric surgery patients will be
randomized and followed up for 6 months. These will be males and females obese (BMI >35) Qatari patients
between the aged 18–60 years. Subjects with renal or liver disease and those with past history of bariatric surgery
will be excluded. By the completion of the trial, patients who took less than 80% of the supplement will be further
excluded from the final analysis. Protein supplement (Cubitan,Protein, Nutricia, Netherlands) that contain daily intake
of 20 g of protein to be taken orally 3 times a day throughout the study period. The placebo group will receive
identical ampule containing zero-protein with exact instructions as per the intervention group. Body weight, muscle
and fat mass, total protein, albumin, vit B12, Magnesium and Zinc will be measured at baseline and every follow
up/study visit. Study variables will be compared between the 2 groups at different stages of the trial, including
baseline, using Sample T-test (paired and unpaired) and the significance level will be confirmed with the 95%
confidence interval with alpha error set to 0.05.
Ethics and dissemination: Protein supplementation for post-bariatric patients is not yet a standard procedure at
Hamad Medical Corporation in Qatar and requires an RCT to establish evidence-based clinical practice guidelines.
This study was approved by the Hamad Medical Corporation IRB and MRC committees (approval no. 16433/16).
Trial registration: ClinicalTrials.gov NCT03147456 (registration date: 18 April 2017).
Strengths and limitations of this study: One major strength of our study is that our population is a distinctive
population (Qatari Obese patients) where results from international studies may not apply to the local and unique
context. A local study like ours will provide healthcare providers in Qatar an opportunity to ensure good clinical
practice and healthy and sustainable weight loss following bariatric surgery.
The well-designed double-blinded RCT will almost certainly provide us with the evidence-based clinical practice
guideline that we seek as health professionals.
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One limitation of our study is the slight discrepancy in caloric content of the intervention and the placebo (250 cal
and 100 cal, respectively). However, it is the intervention that has the higher caloric content, in which case it may
not influence the results in the direction of our hypothesis that protein supplementation leads to lower fat mass
and higher muscle mass.
Another limitation is that the use of the intervention and the placebo are not objectively measured. However, all
efforts will be made to ensure compliance and reporting of consumption of products.
A third limitation could be loss to follow up. Participants may cease to participate, particularly, once they have lost
“sufficient’ weight and gained the fitness to consume any type of foods they desire. This is common in late stages
of post-bariatric surgery (beyond 3 months). We feel that this may be a challenge, particularly in reference to our
specific population. However, such findings albeit negative, should serve in improving the clinical practice delivered
by healthcare providers.
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Background
Obesity is a chronic medical condition characterized by
an accumulation of excess fat in the body that may lead
to negative health consequences. It is the major con-
tributor to some of the most prevalent chronic condi-
tions, such as type 2 diabetes (T2D), heart and kidney
diseases, metabolic syndrome, sleep apnea, and depres-
sion (National Institutes of Health, [5]; Ogden, 2007).
Obesity is the fifth leading risk factor for deaths globally,
making it an extremely important public health issue [6].
In 2014, a World Health Organization (WHO) report
showed that more than 1.9 billion adults aged 18 years
and older were overweight with over 600 million being
obese (see Table 1 for obesity classification). In addition,
44% of the diabetes burden, 23% of heart disease burden,
and 7–41% of certain cancer burdens are associated with
overweight and obesity [10]. Around 2.8 million people
die each year as a result of being overweight or obese.
The majority of these deaths is premature and prevent-
able and may apply an economic burden on the health
systems [7].
Attempts to reverse obesity through weight loss
have been the focus of the attention of many, includ-
ing researchers, scientists and clinicians. This has
been chiefly achieved via dietary and lifestyle modifi-
cation, however, when these have not been successful,
surgical options have been adopted for morbidly
obese patients (ASMBS). Bariatric surgery (BS) has
been shown to be the most effective type of approach
to achieve and sustain significant weight loss in
morbidly obese people [9]. BS is defined as a group
of surgical procedures performed to facilitate substan-
tial weight loss by reducing the size of the stomach
and/or limiting absorption in the small intestine
(American Society for Metabolic and Bariatric Surgery
[1]. It is considered a highly efficacious treatment for
extreme obesity. However, bariatric surgery patients
frequently report difficulty initiating and maintaining
healthy behavioral changes following surgery [4]. Most
Post-bariatric surgery patients are strictly placed on
liquid diet during the early post-operative phase and
are practically unable to consume large quantities of
food in one sitting or taking solid protein within the
first months, which put them at a higher risk of
developing protein malnutrition [8].
Post-surgery multivitamin and high protein supple-
mentation is important to avoid any nutrient deficiency
[3]. High protein supplements are mainly rich in protein
and supplemented with vitamins and minerals. These
supplements in general are inexpensive, widely distrib-
uted, and commonly used by people or patients who
need nutritional supplementation while recovering from
an illness or post-surgery especially post-bariatric sur-
gery [3].
Protein supplementation is an effective approach to
ensuring that post-bariatric surgery patients maintain
muscle mass and healthy levels of the above-mentioned
nutrients and body compositions [2]. In the absence of
this, the weight loss achieved by the surgery may present
a systematic issue leading to higher fat percentage and
lack of these important elements that are essential for
the function of the human physiology. The imbalance of
such essential body compositions and nutrient can also
lead to pathological and irreversible conditions. The
objective of the present study is to examine the effect-
iveness of protein supplementation in reducing the
risk of developing protein malnutrition that lead to
low muscle mass and low protein level, in post-
bariatric surgery patients.
Study objectives
Primary objective
To estimate the difference in change of muscle and fat
mass between participants who received protein supple-
ment and those who received the placebo.
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Secondary objectives
 The percentage of weight reduction in the
intervention in comparison with control group
 The difference in protein level (albumin/total
protein) in post-bariatric patients receiving
intervention compared with control group
 The blood level changes in Vit B12, Magnesium and
Zinc in the intervention group in comparison with
the control group
 The differences in the above changes in relation to
types of bariatric surgery
Study hypothesis
Protein supplementation in Qatari post-bariatric patients
may improve or prevent the imbalance in the body’s
essential proteins and nutrients and avoid muscle
wasting and other undesirable health conditions.
Methods and design
This study is a double-blinded randomized control trial
where both investigators and participants will be blinded
to the treatment (intervention and placebo products are
identical and unlabeled). The researchers will recruit
participants early 2017. The randomization will be done
on a weekly basis within blocks of 8 or 10 patients. This
is roughly the number of patients available per week. A
simple randomization process will be employed to assign
patients to either groups- intervention & placebo. Using
a computer generated random list, the treatment and
the placebo will be allocated in a random manner to
numbers that label individual patients. For the blinding,
a dietician will assign the treatment and the control to
patients as per the randomization results.
Both the intervention and control groups will receive
standard dietary instructions in post-bariatric surgery
period including hospital stay (1–2 days) and every
month thereafter. The intervention group will receive
protein supplement and the placebo group zero-protein
supplement everyday over the study period (6 months).
The placebo & the protein supplement slightly differ in
the caloric content (the difference is 150 kcal/bottle).
Although this difference is not clinically significant,
particularly for the early post-operative phase, this issue
will be addressed as a limitation for this study.
Investigators and researchers, including providers of
care (rehab staff ) in this study will be blinded to the
intervention, i.e. they will not be aware of who is on pro-
tein supplement and who is on placebo. Patients will
also be blinded to the intervention, i.e. they will not be
aware whether they are taking protein or zero protein
supplement. This dietitian is also responsible for filling
the intervention & control ready-to-feed shakes into
identical bottles labeled either A or B. The dietician will
not have any other responsibility such as data entry or
follow up of participants, as this will be done by the PI
and research team. Un-blinding will be unlikely within
the settings of our trial, however, any suspicion of un-
blinding will be dealt with appropriately and may result
into the cessation of participation in the trial.
Study participants
The recruitment of participants for this RCT is based at
Hamad General Hospital. Patients who will undergo
bariatric surgery and fulfill our inclusion and exclusion
criteria will be randomized to either the intervention or
the control arm of the study. The catchment area for
Hamad General Hospital can include the entire Doha
district and the surrounding metropolitan areas. How-
ever, admission to the hospital may also include other
regional areas, thereby making the sample of our popu-
lation representative of the entire Qatari population.
Inclusion criteria
Study participants had the following criteria in order to
participate in the trial:
1. Qatari males or females.
2. Aged between 18 and 60 years
3. Based at the bariatric surgery list of Hamad Medical
Corporation (HMC) with their follow up scheduled
be at HMC (see appendices).
4. Patients who consent to participate in the 6 months
trial
Table 1 World Health Organization Body Mass Index (BMI)
classification for adults
Principal cut-off points Additional cut-off points
Underweight <18.50 <18.50
Severe thinness <16.00 <16.00
Moderate thinness 16.00–16.99 16.00–16.99
Mild thinness 17.00–18.49 17.00–18.49
Normal range 18.50–24.99 18.50–22.99
23.00–24.99
Overweight ≥25.00 ≥25.00
Pre-obese 25.00–29.99 25.00–27.49
27.50–29.99
Obese ≥30.00 ≥30.00
Obese class I 30.00–34.99 30.00–32.49
32.50–34.99
Obese class II 35.00–39.99 35.00–37.49
37.50–39.99
Obese class III ≥40.00 ≥40.00
Source: Adapted from WHO, 1995, WHO, 2000 and WHO 2004
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Exclusion criteria
Patients will be excluded from participating in the trial if
they have the following criteria:
1. Any Renal or liver disease because that may affect
protein or albumin level in body.
2. Past history of bariatric surgery (Gastric Band &
Gastric bypass)
3. Patients will be further excluded after starting the
trial if they did not take at least 80% (minimum 24
bottles per month) of their allocated intervention or
placebo products throughout the trial.
Sample size
The study population are bariatric patients admitted to
bariatric department for surgery based on their eligibility
criteria (BMI ≥ 35). All patients will be enrolled in the
study prior to admission and will be given the interven-
tion or the placebo on the first day post-surgery,
depending on their randomization. A total of 160 obese
Qatari adults from Bariatric and Metabolic Center in
Hamad General Hospital (HGH), who fulfill HGH entry
criteria for bariatric surgery, are expected to be enrolled
in this experimental study.
Using the primary outcome estimates available in the
published study (Schollenberger, A E et al.; 2016), body
fat mass (BFM) and lean body mass (LBM) (kg) in the
intervention group at baseline, 3 and 6 months (BFM
baseline 78.2 ± 19.1, 3 and 6 months 59.9 ± 15) and
(LBM baseline 65.2 ± 14.2, 3 and 6 months 58.2 ± 10.6)
compared with Placebo group (BFM baseline 68.2 ± 12.0,
3 and 6 months 53.9 ± 11.5) and (LBM baseline 68.9 ±
13.4, 3 and 6 months 62.2 ± 11.3). Considering a 90%
power and a type I error rate of 5%, the required sample
size would be 130 participants (65 in each group),
however, to compensate for possible dropouts, non-
compliance and loss to follow-up an additional 15% to
20% will be added to the above sample size (a total of
160 participants i.e., 80 in each group). The only differ-
ence between the above study population and the popu-
lation of our RCT is that the German study population
were more obese (BMI between 49 and 52). Both studies
looked at the effect of protein supplementation on
muscle and fat mass in post-bariatric surgery patients.
Intervention and control
Intervention
1. All participants will receive nutritional counseling by
a bariatric dietitian as a routine standard of care,
which includes strictly fluid diet for the first months.
(Additional file 1).
2. Before discharge from the hospital, patients will be
provided with the supplement and will be advised by
the dietitian regarding its use (one can per day, over
3–5 intervals, i.e. the bottle will be used over the
entire course of the day through a number between
3 and 5 shots/doses).
3. Each supplement (bottle) contains 20 g of protein,
250Kacl plus different micronutrient and
macronutrient, per 200 ml can (Cubitan,Protein,
Nutricia, Netherlands) (Additional file 2).
Control (placebo)
1. All participants will receive nutritional counseling by
a bariatric dietitian as a routine standard of care,
which includes strictly fluid diet for the first months.
(Additional file 2).
2. Before discharge from the hospital, patients will be
provided with the supplement (placebo) and will be
advised by the dietitian regarding its use (one can
per day over 3–5 intervals).
3. Following hospital discharge, Control patients will
receive supplement that contains 0 g protein, fat
free, 100 kcal and enriched with electrolytes per
200 ml can (preOp, Nutricia, Netherlands)
(Additional file 2).
*Note: Both groups will be instructed to take one
supplement pack through the day in equally divided
portions, and, they should store it in room temperature
and drink it without heating.
Materials
The protein supplement, a familiar treatment option at
HMC, consists of whey protein isolate with the following
characteristics:
 Pure Whey Protein Isolate.
 Whey protein isolate is the most pure and
concentrated form of whey protein available.
 Whey protein isolate contains higher protein
content (90–95%) and less lactose (<0.5%). It is a
complete protein with all the indispensable essential
amino acids and is an exceptional source of branch
chain amino acids (BCAAs), especially leucine,
necessary for tissue growth.
 Whey protein is a soluble, easy to digest
protein and is efficiently absorbed into the body
(Marshall, 2004).
 Aside from amino acids, other biological
components of whey protein include lactoferin
(concentration is commonly 0.35–2.0% of total
proteins), immunoglobulins (10–15% of total whey
proteins), lactoperoxidase (accounts for 0.25–0.5%
of total protein in whey), glycomacropeptide
(with 10–15%), and bovine serum albumin
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(10–15% of total whey protein). These bioactive
components together with the essential and
non-essential amino acids help improve body mass
index especially in individuals doing exercise
programs, by enhancing muscle mass and reducing
fat mass. (Marshall, 2004).
 A 200 ml intervention can contains 20 g of protein,
250Kacl plus various micronutrient and
macronutrient.
 A 200 ml placebo can contains 0 g protein, fat free,
100 kcal and enriched with electrolytes, per can
(200 ml).
Measurements
1. Baseline measurement of body composition
(fat mass and muscle mass), height and weight will
be conducted on day one of the trial, using Tanita
body composition instrument and other physical
body measures.
2. Baseline blood test for total protein, albumin, Vit
B12, Zinc and Magnesium levels will be collected.
3. All of the above measurements will be repeated at
1 month, 3 months and at the end of the follow up
period (6 month).
*Note: All of the above measurements and the collection
of blood sample is routine practice for post-bariatric
surgery patient.
Study visits
Patients follow up visit once every month post-surgery
at the Bariatric Dietician Clinic in OPD department at
HGH, and covers the following:
A. Post-surgery dietary advice, to sustain a hypo caloric
and protein-rich diet.
B. Anthropometric parameters for body composition
(see below).
C. All patients will be followed up through weekly
phone calls to ensure compliance and adherence to
the study protocol. Questions such as “how many
bottles of supplements are left?” Or, “how many
bottles have you had so far?” will be asked. Patients
will be asked to use a diary to register their daily use
of the products as well as fill the forms provided by
the hospital in relation to consumption of
supplement.
D. Collection of blood sample will take place following
an overnight fasting. All blood markers will be
measured and calculated in the central laboratory
at HGH.
Body composition (BC)
The measurements of anthropometric data will be done
following overnight fast with patients wearing light
clothes and barefoot (baseline and follow up). Tanita’s
body composition analyzer used for body composition
measurements provides precision in estimating body
Weight, Body Fat Percentage, Body Fat Mass, Body Mass
Index (BMI), Fat Free Mass, and Estimated Muscle Mass
and percentage. Height will be measured using a fixed
wall stadiometer. Both inter- and intra-reliability testing
on all measures, including TanitaHealthWare, are con-
ducted prior to the trial to ensure consistency of the
measures across the study population. This is a standard
hospital procedure and these tests will ensure that the
assessment tools produced are consistent and reliable
measurements.
Blood sample
Blood samples will be collected from patients in (HGH)
laboratory at baseline and every month thereafter follow-
ing an overnight fast. Complete blood count (CBC) will
be used. Total protein, serum Albumin, zinc, magnesium
and vitamin B12 will also be assessed. The laboratories
of HGH are internationally accredited laboratories that
follow international standards.
Data collection and handling
All data obtained from this study will be collected by the
principal investigator and will be saved in a secure loca-
tion where only the project supervisors and a statistician
will be able to access. Data will be de-identified during
and post collection period to ensure privacy and ethical
protocols are maintained. All data will be stored and
kept safe for a period of time according to HMC policy
and will remain a property of HMC. The actual physical
location of all electronic copies will also be at HGH.
Confidentiality of patients will be highly maintained
throughout the trial.
Study timeline
All participants will be followed up for 3 and 6 months
from day one of their participation. Therefore, each ran-
domized pair will have their own follow-up dates, based
on the recruitment pattern at the HGH. For example, a
patient who enters the trial on the 3rd May, he or she
will have the 3 months follow up date on the 3rd August
and the 6th months follow up date on the 3rd
November.
Statistical analysis
Data analyses will be performed using the statistical
software SPSS package 23. The main aim is to analyze
Body composition and other anthropometric changes
throughout the follow up. The normality of the variables
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will be assessed by the Kolmogorov-Smirnov test. Non-
parametric tests will be used in case of non-normal distri-
butions of variables. Characteristics and demographics of
participants will be summarized, based on the assignment
of treatment or placebo, using means and standard devia-
tions (SD) for quantitative variables. Baseline data for the
two groups will be compared using two tailed
independent samples t-tests and the P value of this
difference for each variable will be provided. During the
follow-up, changes in weight, body fat percentage, muscle
mass, total protein level, albumin level, vit B12, Zinc and
Magnesium will be compared within groups using paired
t-test and between groups using independent sample t-
test. In the case of non-normal distribution of variables,
any two independent (unpaired) samples Student’s t test
will be replaced by Mann-Whitney U test. However, in the
case of Two dependent (paired) samples Student’s t test,
Wilcoxon signed rank (paired samples) test will be used.
A multiple linear regression model will also be conducted
to adjust for age and gender will be conducted. Other fun-
damental confounders such as diet intake are not incorpo-
rated into the multiple binary regression model. This is
primarily because post-bariatric patients within the 1st
few months (early post-operative phase) are both unable
and not allowed to take any solid foods and few specific li-
quid foods such as milk and soups are recommended to
them by the dietician. All patients are trained to follow
such diet. Moreover, being an RCT, it is expected that all
confounders (including hidden confounders) are balanced
between the 2 groups and no assessment of baseline
variables such as diet, physical activity and any other bio-
logical differences between the 2 groups is required. This
is consistent with the CONSORT statement for RCTs.
Ethical consideration
1. Patients have the right to refuse participating in the
study.
2. Patients have the right to withdraw from the study
at any time.
3. All patients will be asked to provide consent to
participate by signing the “patient consent form”, as
an agreement to enter the study (Additional file 3).
4. Researchers and other health-care professionals
(investigators) will hold all information about the
patients in strict confidence and disclose it only to
those who have a legal right to this information.
Moreover, patient visits will be conducted in private
rooms.
5. Any information that might lead to the identification
of individual subjects will be omitted.
6. De-identification of data and confidentiality of
patients will be highly maintained throughout the trial
7. “Intervene to protect patients” approach will be
implemented if researchers are highly suspicious
that a risk or abnormal lab value is imminent, and
if necessary, staff will seek advice from more
experienced professionals/clinicians.
Ethical approval was requested from both HMC and
Qatar University IRB committees. Both committees
granted the approval thereby confirming the legitimacy
of our study. The RCT approval number from HMC is
16,433/16 (Additional files 4, 5).
Trial registration
Our clinical trial was registered with ClinicalTrials.gov
(US-NIH) PRS (protocol registration and results system),
ID number: NCT03147453.
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